tert-butyl 4-(4-amino-3-methyl-5-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate | 1054315-49-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-(4-amino-3-methyl-5-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate
• 英文别名: tert-butyl 4-(4-amino-3-methyl-5-nitrophenyl)-5,6-dihydropyridine-1(2H)carboxylate；tert-butyl 4-(4-amino-5-methyl-3-nitrophenyl)-5,6-dihydropyridine-1(2H)-carboxylate；tert-butyl 4-(4-amino-3-methyl-5-nitrophenyl)-5,6-dihydropyridine-1(2H)-carboxylate；tert-butyl 4-(4-amino-3-methyl-5-nitrophenyl)-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 1054315-49-9
• 化学式: C₁₇H₂₃N₃O₄
• 分子量: 333.387
• InChiKey: JQEFXEHWZZAJIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-amino-3-methyl-5-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate 在 三氟乙酸 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 6-甲基-2-硝基-4-(1,2,3,6-四氢吡啶-4-基)苯胺
  参考文献：
  名称：

  辅激活剂精氨酸甲基转移酶1（CARM1）的苯并[ d ]咪唑抑制剂—命中率研究

  摘要：

  领先的优化和SAR的发展导致了共激活剂精氨酸甲基转移酶（CARM1）的有效和选择性苯并[ d ]咪唑抑制剂（17b）的鉴定。

  DOI：

  10.1016/j.bmcl.2009.07.040
• 作为产物：
  描述：

  2-甲基-4-溴苯胺 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 18.5h， 生成 tert-butyl 4-(4-amino-3-methyl-5-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate
  参考文献：
  名称：

  [EN] 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE
  [FR] DÉRIVÉS DE 2-(HÉTÉRO)ARYLBENZIMIDAZOLE ET D'IMIDAZOPYRIDINE COMME INHIBITEURS DE L'ASPARAGINE MÉTHYLTRANSFÉRASE

  摘要：

  取代苯并咪唑和3H-咪唑并[4,5-b]吡啶或式I：其中X和Y分别选自：(i) N和N；和(ii) N和CR4；A2选自：，一个含有2或3个环异原子的C5杂芳基团，其中与L1和核心的键是β相对于彼此的；L1选自：(i)A1-O-CH2-A2；(ii)A1-CH2-O-A2；(iii)A1-C(=O)-NH-A2；(iv)A1-CH(OH)-A2；(v)A1-CH2-NH-C(=O)-A2；(vi) A1-S-CH2-A2；(vii)A1- CH2-S-A2；(viii)A1-CH2-A2；和(ix)A1-CH(CH3)-O-A2；A1是苯基，可选择性地被F或CF3取代；它们作为药物的用途，特别是在治疗癌症和血红蛋白病中。

  公开号：

  WO2014128465A1

文献信息

• Heterocyclic inhibitors of protein arginine methyl transferases
  申请人：Purandare Vinayak Ashok

  公开号：US20060235037A1

  公开（公告）日：2006-10-19

  A compound of formula I, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or solvate thereof, methods of using such compounds in the treatment of hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases; and to pharmaceutical compositions containing such compounds.

  I型化合物的化合物，或其立体异构体、互变异构体、药用可接受的盐或溶剂化物； 使用此类化合物治疗增生性、炎症性、传染性和免疫调节障碍及疾病的方法；以及含有此类化合物的药物组合物。
• 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE
  申请人：CANCER THERAPEUTICS CRC PTY LTD

  公开号：US20160222005A1

  公开（公告）日：2016-08-04

  Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR 4 ; A 2 is selected from: a C 5 heteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are β to one another; L 1 is selected from: (i) A1 —O—CH 2 — A2 ; (ii) A1 —CH 2 —O— A2 ; (iii) A1 —C(═O)—NH— A2 ; (iv) A1 —CH(OH)— A2 ; (v) A1 —CH 2 —NH—C(═O)— A2 ; (vi) A1 —S—CH 2 — A2 ; (vii) A1 —CH 2 —S— A2 ; (viii) A1 —CH 2 — A2 ; and (ix) A1 —CH(CH 3 )—O- A2 ; A1 is phenyl, optionally substituted by F or CF 3 ; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies.

  取代苯并咪唑和3H-咪唑[4,5-b]吡啶或式I：其中X和Y分别从以下选取：（i）N和N；和（ii）N和CR4；A2从选择：一个C5杂环芳基烷基，包含2或3个环杂原子，其中与L1和核心的键是β对于彼此；L1从以下选取：（i）A1-O-CH2-A2；（ii）A1-CH2-O-A2；（iii）A1-C（═O）-NH-A2；（iv）A1-CH（OH）-A2；（v）A1-CH2-NH-C（═O）-A2；（vi）A1-S-CH2-A2；（vii）A1-CH2-S-A2；（viii）A1-CH2-A2；和（ix）A1-CH（CH3）-O-A2；A1是苯基，可以选择性地被F或CF3取代；它们的用途作为药物，特别是用于治疗癌症和血红蛋白病。
• Discovery and Evaluation of 4-(2-(4-chloro-1<i>H</i>-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)pyridin-2(1<i>H</i>)-one (BMS-695735), an Orally Efficacious Inhibitor of Insulin-like Growth Factor-1 Receptor Kinase with Broad Spectrum in Vivo Antitumor Activity
  作者：Upender Velaparthi、Mark Wittman、Peiying Liu、Joan M. Carboni、Francis Y. Lee、Ricardo Attar、Praveen Balimane、Wendy Clarke、Michael W. Sinz、Warren Hurlburt、Karishma Patel、Lorell Discenza、Sean Kim、Marco Gottardis、Ann Greer、Aixin Li、Mark Saulnier、Zheng Yang、Kurt Zimmermann、George Trainor、Dolatrai Vyas

  DOI：10.1021/jm800832q

  日期：2008.10.9

  We previously reported that 1 (BMS-536924), a benzimidazole inhibitor of the insulin-like growth factor-1 receptor, had demonstrated in vivo antitumor activity. This lead compound was found to have potent CYP3A4 inhibition, CYP3A4 induction mediated by PXR transactivation, poor aqueous solubility, and high plasma protein binding. Herein we disclose the evolution of this chemotype to address these issues. This effort led to 10 (BMS-695735), which exhibits improved ADME properties, a low risk for drug-drug interactions, and in vivo efficacy in multiple xenograft models.
• US9856252B2
  申请人：——

  公开号：US9856252B2

  公开（公告）日：2018-01-02
• [EN] HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES<br/>[FR] INHIBITEURS HETEROCYCLIQUES DES PROTEINES ARGININE METHYLE TRANSFERASES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2006113458A1

  公开（公告）日：2006-10-26

  [EN] A compound of formula I, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or solvate thereof, methods of using such compounds in the treatment of hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases; and to pharmaceutical compositions containing such compounds.
  [FR] Composé de formule I, ou un de ses stéréoisomères, de ses tautomères, de ses sels pharmaceutiquement acceptables ou de ses solvates, méthodes d'utilisation de tels composés pour le traitement de troubles et de maladies hyperproliférantes, inflammatoires, infectieuses, et immunomodulatrices ; et compositions pharmaceutiques contenant de tels composés.